In Brief: Procept
Executive Summary
Procept: Initiates a program to develop new drugs for infectious diseases based on research in the CD-1 system of lipid antigen presentation conducted at Brigham & Women's Hospital and Harvard Medical School, the Cambridge, Mass.-based small molecule therapeutics company announces Jan. 10. Initial research will be done in the area of tuberculosis. To fund vaccine development, Procept, biotech execs and researchers joined in November to form VacTex, a financing vehicle that has raised $1 mil. Procept will have an ownership position in VacTex and an option to purchase the entire company...